BCTXZ
BriaCell Therapeutics Corp.Warrants of BriaCell Therapeutics Corp. · BCTX stock page →
—
Market cap
$1.2M
Nano cap
Short interest
🔒 Subscribers only
New fund stakes
0
Q1 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BEARISH 2 reports · latest
Balance 2 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 2/2
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q1 2026: 1 added (0 new), 0 trimmed or exited.
Who's buying
13F· Q1 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $658.00 |
| UBS Group AG | NEAR_EXIT | $1.00 |
| UBS Group AG | NEAR_EXIT | $22.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 14, 2026
FDA
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Sep 8, 2026
Contract
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 24, 2026
Press release
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 5, 2026
FDA
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Jul 16, 2026
FDA
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 FDA
Jun 2, 2026 SEC Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
BriaCell Therapeutics Corp. closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, raising…
8-K — Impact 6/10
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at $3.25 per share via a best-efforts placement agent…
424B5 — Impact 6/10
Mar 31, 2026 Inst.
UBS Group AG — DOUBLED
4,697 shares ($658.00)
Dec 31, 2025 Inst.
UBS Group AG — NEAR_EXIT
5 shares ($1.00)
SecBot reports
2 filings · 0 bullish · 2 bearish- BEARISH 8-KJun 2, 2026
BriaCell Therapeutics Corp. closed a best-efforts offering of 1,449,300 common shares at $3.25 per…
The rapid close of a dilutive offering at a discount, combined with a tiny market cap and ongoing cash burn, signals acute capital needs. Monitor for further dilution or a potential reverse stock…
- BEARISH 424B5Jun 2, 2026
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at $3.25 per share via a…
The dilutive offering at a discount to market price is a clear negative signal for the warrant (BCTXZ). Monitor for further dilution risk given the massive warrant overhang (7.18M shares at $16.22)…
All BCTXZ filing & press-release reports (2)
- 8-K reportJun 2, 2026
- 424B5 reportJun 2, 2026